Samuel Harry Myers

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Greta Bagnolini · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
2. Marinella Roberti · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
3. Stefania Girotto · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
4. Naomi Walsh · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
5. Andrea Cavalli · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
6. Mirco Masi · 2 shared papers, 2024–2025 · strength 0.35
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
7. Shannon R. Nelson · 2 shared papers, 2024–2025 · strength 0.35
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
8. Giovanni Ferrandi · 1 shared paper, 2025 · strength 0.18
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
9. Fabrizio Schipani · 1 shared paper, 2024 · strength 0.18
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.